These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27139168)

  • 1. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group.
    Trallero-Araguás E; Grau-Junyent JM; Labirua-Iturburu A; García-Hernández FJ; Monteagudo-Jiménez M; Fraile-Rodriguez G; Les-Bujanda I; Rodriguez-Carballeira M; Sáez-Comet L; Selva-O'Callaghan A;
    Semin Arthritis Rheum; 2016 Oct; 46(2):225-231. PubMed ID: 27139168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type.
    Johnson C; Connors GR; Oaks J; Han S; Truong A; Richardson B; Lechtzin N; Mammen AL; Casciola-Rosen L; Christopher-Stine L; Danoff SK
    Respir Med; 2014 Oct; 108(10):1542-8. PubMed ID: 25269710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody.
    Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F
    Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease.
    Cavagna L; Caporali R; Abdì-Alì L; Dore R; Meloni F; Montecucco C
    J Rheumatol; 2013 Apr; 40(4):484-92. PubMed ID: 23418387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use.
    Stanciu R; Guiguet M; Musset L; Touitou D; Beigelman C; Rigolet A; Costedoat-Chalumeau N; Allenbach Y; Hervier B; Dubourg O; Maisonobe T; Charuel JL; Behin A; Herson S; Amoura Z; Grenier P; Benveniste O
    J Rheumatol; 2012 Sep; 39(9):1835-9. PubMed ID: 22859355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F
    Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease.
    Cobo-Ibáñez T; López-Longo FJ; Joven B; Carreira PE; Muñoz-Fernández S; Maldonado-Romero V; Larena-Grijalba C; Cubas IL; Muriel ET; Mateos CB; de la Peña Lefebvre PG; Gomez-Gomez A; Nogal LB; Pérez A; Almodovar R; Lojo L; Ruiz-Gutiérrez L; López-Robledillo JC; García de Yébenes MJ; Nuño-Nuño L
    Clin Rheumatol; 2019 Mar; 38(3):803-815. PubMed ID: 30392161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD).
    Rojas-Serrano J; Herrera-Bringas D; Mejía M; Rivero H; Mateos-Toledo H; Figueroa JE
    Clin Rheumatol; 2015 Sep; 34(9):1563-9. PubMed ID: 26219488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease.
    Andersson H; Sem M; Lund MB; Aaløkken TM; Günther A; Walle-Hansen R; Garen T; Molberg Ø
    Rheumatology (Oxford); 2015 Aug; 54(8):1420-8. PubMed ID: 25740830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease.
    Labirua-Iturburu A; Selva-O'Callaghan A; Martínez-Gómez X; Trallero-Araguás E; Labrador-Horrillo M; Vilardell-Tarrés M
    Clin Exp Rheumatol; 2013; 31(3):436-9. PubMed ID: 23465087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Involvement in the Antisynthetase Syndrome: A Comparative Cross-sectional Study.
    Andersson H; Aaløkken TM; Günther A; Mynarek GK; Garen T; Lund MB; Molberg Ø
    J Rheumatol; 2016 Jun; 43(6):1107-13. PubMed ID: 27036381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort.
    Chen F; Wang J; Zhang P; Zuo Y; Ye L; Wang G; Shu X
    Front Immunol; 2022; 13():879266. PubMed ID: 35603153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
    Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C
    J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome.
    Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R
    ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome.
    Marie I; Josse S; Decaux O; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Hachulla E; Vittecoq O; Menard JF; Jouen F; Dominique S
    Eur J Intern Med; 2013 Jul; 24(5):474-9. PubMed ID: 23375620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the clinical features of antisynthetase syndrome: a retrospective cohort study in China.
    Wang R; Zhao Y; Qi F; Wu X; Wang Y; Xu Y; Wu Y; Zhang N; Hou H; Sun W; Li X; Wei W
    Clin Rheumatol; 2023 Mar; 42(3):703-709. PubMed ID: 36308573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity.
    Hervier B; Devilliers H; Stanciu R; Meyer A; Uzunhan Y; Masseau A; Dubucquoi S; Hatron PY; Musset L; Wallaert B; Nunes H; Maisonobe T; Olsson NO; Adoue D; Arlet P; Sibilia J; Guiguet M; Lauque D; Amoura Z; Hachulla E; Hamidou M; Benveniste O
    Autoimmun Rev; 2012 Dec; 12(2):210-7. PubMed ID: 22771754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome.
    Zamora AC; Hoskote SS; Abascal-Bolado B; White D; Cox CW; Ryu JH; Moua T
    Respir Med; 2016 Sep; 118():39-45. PubMed ID: 27578469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
    Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
    J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of anti-Ro-52 antibodies with occurrence of interstitial lung disease in patients with idiopathic inflammatory myopathy.
    Weng CT; Huang TH; Wu CH; Sun YT
    Arthritis Res Ther; 2024 Aug; 26(1):152. PubMed ID: 39175076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.